OR WAIT null SECS
The US Food and Drug Administration (FDA) has extended the emergency use authorization for the Pfizer/BioNTech COVID-19 vaccine to include a booster dose for teenagers aged 16 to 17 years.
The US Food and Drug Administration (FDA) has amended the Pfizer-BioNTech COVID-19 vaccine emergency use authorization (EUA) to expand eligibility of a single booster dose to adolescents aged 16 or 17 years at least 6 months after completion of their primary vaccine series.1
“The Pfizer-BioNtech COVID-19 vaccine has been available to individuals 16 years of age and older for nearly a year, and its benefits have been shown to clearly outweigh potential risks,” said Peter Marks, MD, PhD, director of the FDA’s Center for Biologics Evaluation and Research in an FDA press release. “Since we first authorized the vaccine, new evidence indicates that the vaccine effectiveness against COVID-19 is waning after the second dose of the vaccine for all adults and for those in the 16- and 17-year old age group.”
“A single booster dose of the vaccine for those vaccinated at least 6 months prior will help provide continued protection against COVID-19 in this and older age groups,” Marks added.
The EUA amendment follows a previous agency analysis of immune response data in 200 adults aged between 18 and 55 years who received a single booster dose 6 months after their second Pfizer-BioNTech dose. At 1 month after the booster dose, antibody response against the SARS-CoV-2 virus—compared with the response 1 month after the primary vaccine series—demonstrated a booster response. The agency, therefore, has concluded that these data “support extending the eligible booster age population to 16- and 17-year-olds.”
The FDA also noted that the benefits of a single booster dose outweighed any risk of myocarditis or pericarditis in this age group.
Pfizer continues to conduct postauthorization/postmarketing studies to assess the “known serious risks” of both myocarditis and pericarditis.
“As people gather indoors with family and friends for the holidays, we can’t let up on all the preventive public health measures we have been taking during the pandemic,” said Acting FDA Commissioner Janet Woodcock, MD. “With both the Delta and Omicron variants continuing to spread, vaccination remains the best protection against COVID-19.”